Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.

J Investig Allergol Clin Immunol. 2017 Jun;27(Suppl. 1):1-352

Authors: Dominguez-Ortega J, Delgado J, Blanco C, Prieto L, Arroabarren E, Cimarra M, Henriquez-Santana A, Iglesias-Souto J, Vega-Chicote JM, Tabar AI

Abstract
Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients.

[PDF full-Text]

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @Aller_MD: Top story: The list of diseases linked to air pollution is growing | Science Ne… https://t.co/NpGbgxPSxf, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: “Dupixent for Atopic Dermatitis Aims for EU Approval” https://t.co/tHqjNe1Bt2 https://t.co/GBO9AwFmN8
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: How to Use Your LinkedIn 'Following' List for Marketing Outreach | S… https://t.co/GI12wZmtHF, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: Top story: Bill Gates: More Tech Revolutions Are Coming, And They'll Change Eve… https://t.co/pFyfMleKVh, see more https://t.…
1hreplyretweetfavorite
Interasma RT @Aller_MD: Passive blood #anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction https://t.co/uF
1hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma